How India Exports Azithromycin to the World

In the United States, azithromycin is approved for various formulations, including oral tablets, capsules, suspensions, and injections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for azithromycin, indicating a competitive generic market. Notably, the brand-name drug Zithromax, manufactured by Pfizer, received its initial approval on November 1, 1991, for the 250 mg capsule formulation. Subsequent approvals encompassed various strengths and formulations, such as oral suspensions and tablets. The presence of numerous ANDA approvals underscores the robust participation of Indian exporters in supplying azithromycin to the U.S. market.

Regarding import alerts, as of March 2026, there are no active FDA import alerts specifically targeting azithromycin products from India. However, Indian manufacturers must adhere to the FDA's stringent regulatory requirements, including compliance with Current Good Manufacturing Practices (cGMP) and successful facility inspections, to maintain market access.

In the European Union, azithromycin-containing medicinal products are subject to national marketing authorizations. In September 2025, the European Medicines Agency (EMA) concluded a referral procedure concerning azithromycin for systemic use, resulting in a legally binding decision applicable across all EU Member States. This decision emphasized the importance of monitoring azithromycin's safety profile and ensuring its appropriate use to mitigate antimicrobial resistance risks. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with the EMA's directives and requires that azithromycin products meet the EU's Good Manufacturing Practice (GMP) standards. Indian exporters must ensure compliance with these standards to access the UK market.

Azithromycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in treating various bacterial infections. In June 2017, the WHO added azithromycin to its Essential Medicines List to facilitate yaws eradication efforts. (who.int) The antibiotic is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, azithromycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, azithromycin is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and international quality standards.

Azithromycin's original patent, held by Pliva, was filed in 1981 and expired in 2005, leading to the introduction of generic versions globally. (wipo.int) The absence of active patents has resulted in significant generic competition, with numerous manufacturers, including Indian companies, producing and exporting azithromycin to various international markets.

In November 2025, the WHO released new Target Product Profiles (TPPs) for pediatric formulations of azithromycin, aiming to accelerate access to better medicines for children. (who.int) This initiative is expected to drive demand for age-appropriate azithromycin formulations, presenting opportunities for Indian exporters specializing in pediatric medicines.

In September 2025, the EMA concluded a referral procedure for azithromycin-containing medicinal products for systemic use, resulting in a legally binding decision across EU Member States. (ema.europa.eu) This decision underscores the importance of monitoring azithromycin's safety profile and ensuring its appropriate use to mitigate antimicrobial resistance risks.

In June 2025, the WHO published a fact sheet highlighting the increasing resistance of Neisseria gonorrhoeae to azithromycin, emphasizing the need for prudent antibiotic use and the development of new treatment guidelines. (who.int) This development may influence prescribing practices and demand for azithromycin in certain markets.

In March 2025, the WHO reported on the use of azithromycin in mass drug administration campaigns for yaws eradication, noting significant progress in countries like Papua New Guinea and the Solomon Islands. (who.int) These efforts highlight the continued global reliance on azithromycin for public health initiatives.

In January 2025, the WHO emphasized the inclusion of azithromycin in its Model List of Essential Medicines for Children, reflecting its critical role in treating pediatric infections and guiding procurement decisions worldwide. (who.int)

These developments underscore the dynamic regulatory and market landscape for azithromycin, necessitating continuous monitoring by Indian exporters to maintain compliance and capitalize on emerging opportunities.

India's pharmaceutical industry, renowned as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 70% of India's APIs are sourced from China, with some critical antibiotics like azithromycin being nearly 100% dependent on Chinese imports. (cidrap.umn.edu) This dependency exposes the supply chain to significant risks, as disruptions in Chinese manufacturing or export policies can directly impact India's pharmaceutical output.

The COVID-19 pandemic underscored this vulnerability. During the crisis, prices of APIs imported from China more than doubled, leading to increased production costs and potential drug shortages. (cidrap.umn.edu) Such price volatility and supply disruptions highlight the critical need for India to diversify its KSM and API sourcing to ensure a more resilient pharmaceutical supply chain.

Analysis of TransData Nexus's proprietary trade data reveals that the top five exporters of azithromycin from India account for 32.6% of the total export value, with LINCOLN PHARMACEUTICALS LTD leading at a 10.4% share. This concentration indicates a moderate risk, as reliance on a limited number of suppliers can lead to supply disruptions if any of these key players face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API production and reducing import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, which are essential for antibiotics production. While these initiatives are steps toward reducing single-source risks, their impact on azithromycin's supply chain remains to be fully realized.

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. On February 28, 2026, the US and Israel launched joint attacks on Iran, leading to the closure of the Strait of Hormuz, a vital passage through which approximately 20% of global oil transits. This closure has disrupted the supply of raw materials and increased shipping costs, affecting industries worldwide, including pharmaceuticals.

Additionally, the Red Sea and the Bab al-Mandab Strait have experienced disruptions due to activities by Iran-backed Houthi forces, further complicating shipping routes. These geopolitical events have led to increased transit times and costs, posing challenges to the timely delivery of pharmaceutical products.

• Diversify API and KSM Sourcing: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country, particularly for critical antibiotics like azithromycin.

• Enhance Domestic Production: Accelerate initiatives under the PLI scheme to boost local manufacturing of APIs and KSMs, thereby strengthening the domestic supply chain.

• Strengthen Supplier Relationships: Foster long-term partnerships with multiple suppliers to ensure a more stable and reliable supply chain.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains, enabling proactive risk management.

• Invest in Supply Chain Resilience: Implement strategies such as maintaining strategic stockpiles and developing flexible logistics networks to adapt to disruptions.

RISK_LEVEL: MEDIUM